Future Growth Forecast For The CAR-T Therapy Global Market 2023-2032
The Business Research Company’s global market reports provide comprehensive analysis on the various markets in 27 industries across 60 geographies.
- Market Expansion: The global CAR-T therapy pipeline analysis market has witnessed substantial growth, surging from $1.8 billion in 2022 to $2.25 billion in 2023, marking a remarkable compound annual growth rate (CAGR) of 25.0%.
- Future Projections: Anticipated growth continues, with the market size projected to reach $3.9 billion in 2027, maintaining a steady CAGR of 14.7%.
Driving Forces Behind CAR-T Therapy Market
- Financial Support: A key driver of the CAR-T therapy market is the increasing financial support from various organizations dedicated to advancing CAR-T therapy development and accessibility.
- Government Initiatives: Government and non-government organizations contribute financial support for both research and development by companies and the treatment of acute lymphoblastic leukemia (ALL) patients.
- Exemplary Case: The University of California San Diego School of Medicine received a grant of US$ 4.1 million in December 2021 from the California Institute for Regenerative Medicine, further illustrating the financial backing driving CAR-T therapy development.
Key Players in the CAR-T Therapy Market
- Market Leaders: Major players shaping the chimeric antigen receptor (CAR)-T therapy market include Novartis AG, Kite Pharma, Pfizer Inc., Juno Therapeutics, Celgene Corporation, CARsgen Therapeutics, Sorrento Therapeutics, Legend Biotech, Mustang Bio, and Immune Therapeutics.
- Clinical Trials: Companies are actively conducting clinical trials to assess the effectiveness of CAR-T therapy in treating multiple myeloma, a type of white blood cell cancer that accumulates in the bone marrow.
- Targeting Multiple Myeloma: CAR-T therapy is being explored as a treatment for relapsed or refractory multiple myeloma (RRMM), with Novartis introducing T-Charge™, a next-generation CAR-T platform, in December 2021.
Advancements in CAR-T Therapy
- Next-Generation Platform: Novartis announced the introduction of T-Charge™ as a next-generation CAR-T platform, serving as the foundation for various investigational CAR-T cell therapies in their pipeline.
- Early Clinical Stage: T-Charge™ was in the early clinical stage (Phase I), showcasing the ongoing commitment to advancing CAR-T therapy for multiple myeloma and other applications.
The global CAR-T therapy pipeline analysis market is comprehensively segmented to provide insights into its diverse landscape:
- By Type:
- Combination Therapy
- By Target Antigen:
- Other Target Antigens
- By Application:
- Acute Lymphoblastic Leukemia
- Diffuse Large B-Cell Lymphoma
- Follicular Lymphoma
- Chronic Lymphocytic Leukemia
- Multiple Myeloma
- Other Applications
- North America Leadership: North America emerged as the largest region in the CAR-T therapy market in 2022, highlighting the region’s significant contribution to advancing and adopting this revolutionary cancer treatment.
View More On The CAR-T Therapy Market Report 2023 – https://www.thebusinessresearchcompany.com/report/car-t-therapy-global-market-report
Request A Sample Of The Global CAR-T Therapy Market Report 2023:
The CAR-T Therapy Global Market Report 2023 provides a comprehensive overview on the CAR-T therapy market size, trends and drivers, opportunities, strategies, and companies analysis. Through our reports businesses can effectively analyze data and frame well-informed strategies
View More Related Reports –
Coronavirus (COVID-19) Current Therapy Global Market Report 2023
Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Global Market Report 2023
Bioinformatics Global Market Report 2023
Follow us on:
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model